My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Verrica Pharmaceuticals Inc. - Common Stock (NQ:VRCA)

5.690 +0.130 (+2.34%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Verrica Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

VRCA Stock Earnings: Verrica Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 ↗

August 14, 2024

VRCA stock results show that Verrica Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

US Stocks Mixed; Inflation Rate Falls More Than Projected ↗

August 14, 2024

Via Benzinga

Topics Economy

Why Is Dermatology-Focused Verrica Pharmaceuticals Stock Trading Lower On Wednesday? ↗

August 14, 2024

Verrica Pharmaceuticals shares positive preliminary results from Part 2 of its Phase 2 trial for VP-315 in treating basal cell carcinoma, showing promising tumor reduction and safety. No serious...

Via Benzinga

7 Short-Squeeze Stocks That Could Beat Down the Bears ↗

July 15, 2024

Panic can be a cruel emotion, especially when the consequences are uncapped red ink.

Via InvestorPlace

Planet Fitness To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

May 14, 2024

Via Benzinga

Earnings Scheduled For February 29, 2024 ↗

February 29, 2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.

Via Benzinga

Earnings Outlook For Verrica Pharmaceuticals ↗

February 28, 2024

Via Benzinga

7 Analysts Have This to Say About Verrica Pharmaceuticals ↗

October 12, 2023

Via Benzinga

Analyst Ratings for Verrica Pharmaceuticals ↗

August 10, 2023

Via Benzinga

VRCA Stock Earnings: Verrica Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 ↗

May 13, 2024

VRCA stock results show that Verrica Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

7 Potential Short-Squeeze Stocks Poised for Rapid Gains ↗

January 22, 2024

Giving the bears a rough time can yield massive gains for contrarians, thus drawing attention to these potential short-squeeze stocks.

Via InvestorPlace

Top 4 Health Care Stocks That May Crash This Month ↗

December 20, 2023

As of Dec. 20, 2023, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Via Benzinga

Insiders Buying Pfizer And 3 Other Stocks ↗

December 20, 2023

Although U.S. stocks closed higher on Tuesday, there were a few notable insider trades.

Via Benzinga

Why Is Verrica Pharmaceuticals (VRCA) Stock Up 40% Today? ↗

December 15, 2023

With Verrica Pharmaceuticals releasing positive Phase 3 trial results for a skin disease therapeutic, VRCA stock skyrocketed in response.

Via InvestorPlace

Why Quanex Building Products Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

December 15, 2023

Shares of Quanex Building Products Corporation (NYSE: NX) moved lower during Friday’s session after the company reported fourth-quarter financial results. Quanex Building Products shares fell 10.7% to...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

December 15, 2023

Via Benzinga

Why Is Skin Disease-Focused Verrica Pharmaceuticals Stock Trading Higher Today? ↗

December 15, 2023

Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) development and commercialization partner, Torii Pharmaceutical Co Ltd, reported topline results from its Phase 3 trial of TO-208 (referred to as VP-102 and...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

December 15, 2023

Via Benzinga

HC Wainwright & Co. Maintains Buy Rating for Verrica Pharmaceuticals: Here's What You Need To Know ↗

July 27, 2023

Via Benzinga

Verrica's Ycanth Unlikely to Face Near-Term Competition, Analyst Upgrades Stock On FDA Approval ↗

July 25, 2023

Monday, the FDA approved Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) Ycanth (cantharidin) topical solution for molluscum contagiosum (molluscum) in adult and pediatric patients

Via Benzinga

Earnings Scheduled For November 9, 2023 ↗

November 09, 2023

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 25, 2023 ↗

July 25, 2023

Via Benzinga

$1M Bet On Verrica Pharmaceuticals? Check Out These 3 Stocks Insiders Are Buying ↗

July 25, 2023

Although US stocks closed higher on Monday, there were a few notable insider trades.

Via Benzinga

Why Shares of Verrica Pharmaceuticals Are Plummeting on Monday ↗

July 24, 2023

The company's shares dropped because it will require financing to help launch its first marketed product.

Via The Motley Fool

Why Ryanair Holdings Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

July 24, 2023

Gainers Tupperware Brands Corporation (NYSE: TUP) shares jumped 59% to $1.43 on above-average volume amid retail investor interest.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

July 24, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

July 24, 2023

Via Benzinga

FDA Approves Verrica Pharma's Ycanth: First Treatment Of Molluscum Contagiosum Impacting 6M People In US ↗

July 24, 2023

The FDA approved Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) Ycanth (cantharidin) topical solution for molluscum contagiosum (molluscum) in adult and pediatric patients

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

July 21, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

May 29, 2023

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.